Oncology Briefings™ Melanoma: Uncovering the Potential Impact of IO + BRAF/MEK Triplet Combinations

Release Date: November 13, 2020
Expiration Date: November 13, 2021

Activity Overview

This online activity is designed to update oncologists on recent data presented and published in 2020 on emerging combination therapy regimens for metastatic melanoma. Oncology Briefings™ Melanoma: Uncovering the Potential Impact of IO + BRAF/MEK Triplet Combinations uses text-based and faculty audio summaries to review findings of studies exploring triplet regimens in metastatic, BRAF-mutated melanoma. These findings are accompanied by expert commentary on the use of novel treatment regimens and future directions for the field. This activity will provide insight into how clinicians can apply recent findings into clinical practice to improve patient care.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Target Audience

This educational activity is directed toward medical oncologists who treat patients with melanoma. Pathologists, histologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of melanoma will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess recent advances in understanding of melanoma treatment that provide the mechanistic rationale for BRAF/MEK inhibitor and immunotherapeutic combination strategies in the context of current management paradigms
• Outline key aspects and efficacy profiles of ongoing clinical trials examining emerging BRAF/MEK and immunotherapeutic triplet combination strategies in melanoma
• Apply knowledge of efficacy profiles on emerging triplet combination approaches to inform potential sequencing decisions to optimize outcomes among patients with advanced melanoma
• Discuss best practices to proactively identify and manage adverse events associated with combination strategies in advanced melanoma treatment

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Allison Betof Warner, MD, PhD
Assistant Attending Physician
Melanoma Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: Iovance Biotherapeutics, Nanobiotix; Other: LG Chem Life Sciences.

Ryan Sullivan, MD
Assistant Professor, Medicine
Harvard Medical School
Assistant Professor, Hematology/Oncology
Massachusetts General Hospital
Boston, MA

Disclosures: Grant/Research Support: Merck; Consultant: Asana BioSciences, AstraZeneca, Covance, Eisai, Merck, Novartis, Pfizer, Replimune Group Inc.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.